Skip to main content

Table 2 Comparison of univariate covariates

From: Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery

   Before PSM P-value   After PSM P-value
Characteristics Chemotherapy-
(n = 1055)
Chemotherapy+
(n = 1589)
Chemotherapy-
(n = 925)
Chemotherapy+
(n = 925)
Age    < 0.001    0.254
  ≤ 45 161 (15.3) 273 (17.2)   159 (17.2) 183 (19.8)  
 45–65 538 (51.0) 946 (59.5)   504 (54.5) 503 (54.4)  
  > 65 356 (33.7) 370 (23.3)   262 (28.3) 239 (25.8)  
Race    0.086    0.124
 White 911 (86.4) 1332 (83.8)   793 (85.7) 768 (83.0)  
 Non-white 144 (13.6) 257 (16.2)   132 (14.3) 157 (17.0)  
Stage    < 0.001    0.328
 IA 626 (59.3) 544 (34.2)   499 (53.9) 475 (51.4)  
 IB 60 (5.7) 92 (5.8)   57 (6.2) 49 (5.3)  
 IC 283 (26.8) 731 (46.0)   283 (30.6) 319 (34.5)  
 IIA 86 (8.2) 222 (14.0)   86 (9.3) 82 (8.9)  
Grade    < 0.001    0.530
 1 721 (68.3) 841 (52.9)   595 (64.3) 581 (62.8)  
 2 334 (31.7) 748 (47.1)   330 (35.7) 344 (37.2)  
Laterality    < 0.001    0.147
 Right 477 (45.2) 635 (40.0)   407 (44.0) 383 (41.4)  
 Left 461 (43.7) 660 (41.5)   405 (43.8) 401 (43.4)  
 Other/Unknown 117 (11.1) 294 (18.5)   113 (12.2) 141 (15.2)  
Tumor size, cm    0.044    0.888
  ≤ 10 464 (44.0) 707 (44.5)   414 (44.8) 416 (45.0)  
  > 10 429 (40.7) 690 (43.4)   386 (41.7) 391 (42.3)  
 Unknown 162 (15.4) 192 (12.1)   125 (13.5) 118 (12.8)  
Histology    0.001    0.226
 Serous 289 (27.4) 532 (33.5)   257 (27.8) 233 (25.2)  
 Endometrioid 766 (72.6) 1057 (66.5)   668 (72.2) 692 (74.8)  
  1. Data are expressed as n (%). P < 0.05 was considered to indicate a statistically significant difference. PSM propensity score matching